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Abstract
G protein-coupled receptor 68 (GPR68) is an understudied orphan G protein-coupled receptor 
(GPCR). It is expressed most abundantly in the brain, potentially playing important roles in 
learning and memory. Pharmacological studies with GPR68 have been hindered by lack of 
chemical tools that can selectively modulate its activity. We previously reported the first small-
molecule positive allosteric modulator (PAM), ogerin (1), and showed that 1 can potentiate proton 
activity at the GPR6n-Gs pathway. Here, we report the first comprehensive structure-activity 
relationship (SAR) study on the scaffold of 1. Our lead compound resulted from this study, 
MS48107 (71), displayed 33-fold increased allosteric activity compared to 1. Compound 71 
demonstrated high selectivity over closely related proton GPCRs and 48 common drug targets, and 
was bioavailable and brain-penetrant in mice. Thus, our SAR study has resulted in an improved 
GPR68 PAM for investigating the physiological and pathophysiological roles of GPR68 in vitro 
and in vivo.
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G protein-coupled receptor 68 (GPR68) was originally discovered as a clinically related 
receptor in an ovarian cancer cell line as “OGR1” for ovarian cancer G protein-coupled 
receptor.1 While it is widely expressed in most cells and tissues, including spleen, testes, 
small intestine, peripheral blood leukocytes, heart, lung, placenta, kidney, and bone,1,2 it is 
most abundantly expressed in the brain, particularly in the hippocampus3—the brain region 
that is critical for learning and memory. Despite being known for over two decades, GPR68 
remains an understudied orphan G protein-coupled receptor (GPCR) according to IUPHAR.
4 Generally known as a proton-sensing GPCR, it couples to multiple signaling pathways 
through various G proteins (Gs, Gq, Gi, and G12/13) in different cells.2,5–7 However, it 
remains to be established whether GPR68 couples to the β-arrestin signaling pathway. 
Consistent with its capacity to couple to multiple signaling pathways and its wide expression 
pattern, GPR68 has been implicated in many biological processes, including pH 
homeostasis,2,8 tumor growth and metastasis,6,7,9–11 inflammation,12–14 osteoclast 
development,9,15,16 insulin secretion,17,18 and epithelial barrier function.19,20 Interestingly, 
the receptor also functions as a mechanotransducer that senses blood flow (shear stress) in 
arteries, thus modulating vascular physiology.21 Thus, GPR68, a potentially important 
therapeutic target, is one of the National Institutes of Health (NIH)’s Illuminating the 
Druggable Genome GPCRs.22 Presently, the underlying molecular mechanisms have not 
been determined between proton-sensing and these physiological or pathological processes. 
Pharmacological studies of GPR68 have previously been hindered by the lack of small-
molecule ligands. It is clear that potent and selective GPR68 ligands that can be used to 
activate or block its activity are urgently needed to elucidate GPR68 pharmacology and 
clarify its potential roles in the aforementioned biological processes.23
Previous studies have shown that receptor activity is reduced or completely lost if 
extracellular histidine residues are mutated, presumably by affecting protonation states 
responding to extracellular pH changes.2 Therefore, it was proposed that alkaline pH 
conditions stabilize GPR68 in an inactive conformation by hydrogen-bonding interactions 
involving extracellular histidine residues, while acidification and histidine protonation break 
hydrogen-bond interactions, initiating receptor activation.2 The putative histidine-binding 
sites for protons are scattered throughout different extracellular loops rendering challenges 
to directly activate or block this receptor with orthosteric ligands. This, in turn, makes 
allosteric binding site more attractive to target as with many other GPCRs.24,25 Allosteric 
modulators rely on endogenous protons to produce function and can preserve the spatial and 
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temporal nature of the proton-mediated activation of GPR68. Allosteric modulators bind to 
GPR68 at a site different from that of protons and function by fine-tuning proton activity 
through increasing or reducing proton affinity (α-cooperativity), efficacy (β-cooperativity), 
or both.
For conventional GPCRs, such as metabotropic glutamate receptors (mGluRs), binding and 
functional assays can be carried out in biological systems that the concentration of the 
orthosteric ligand (i.e., glutamate) can be controlled. However, for GPR68, the orthosteric 
ligand is proton, which always presents in the receptor compartment. Therefore, the 
allosteric binding affinity (KB), defined as the dissociation equilibrium constant of allosteric 
modulator in the absence of orthosteric ligand (i.e., proton), does not have corresponding 
biological meaning and cannot be measured in binding assays. Instead, we can estimate the 
allosteric affinity cooperativity α, efficacy cooperativity β, and allosteric binding affinity KB 
from functional assays according to the standard allosteric operational model.26–28 The 
observed binding affinity of allosteric modulators can be calculated by the equation KB = (1 
+ [A]/KA)/(1 + α[A]/KA), where [A] is the proton concentration and KA is the equilibrium 
dissociation constant of protons at GPR68 in the absence of modulators. In structure-activity 
relationship (SAR) studies, we actually can optimize the potency of the modulators in 
proton-mediated signaling by optimizing α, β, and/or KB. In contrast to traditional 
orthosteric agonists or antagonists which rely on binding affinity (Ki) for selectivity, 
allosteric modulators achieve high selectivity through allosteric αβ cooperativity in addition 
to allosteric binding affinity (KB).29,30 The overall allosteric activity can be quantified with a 
characteristic allosteric index, Log(αβ/KB),31 which contains information about allosteric 
cooperativity and can be calculated and used as a guiding parameter for SAR studies and 
optimization.29,32
Development of small-molecule ligands for GPR68 remains a challenging task. A small 
number of isoxazole compounds have been reported to possess GPR68 agonist activity.33 
However, several reports suggested that the weak activity of isoxazoles could be nonspecific.
12,34 Divalent metal ions, such as Cu2+ and Zn2+, were initially used to inhibit GPR68 
activity.2,19 Recently, these divalent ions, in addition to Co2+ and Mn2+, have been reported 
to be GPR68 agonists.35–37 However, these recent reports neither achieved full pH control 
nor used a broad enough pH range to address potential allosteric mechanisms. In addition, 
Zn2+ is a well-known allosteric modulator for the orphan receptor GPR39.38–40 Moreover, 
these divalent ions are biologically important metals or trace elements and play critical roles 
in many biological processes.41–43 Therefore, these divalent metals are unlikely GPR68 
selective tools.
In 2015, we reported the discovery of ogerin (1) as the first positive allosteric modulator 
(PAM) of GPR68.44 Compound 1 potentiates proton activity in GPR68-mediated Gs−cAMP 
production, but has no activity at related proton-sensing GPCRs, including GPR4 and 
GPR65. This selective ligand led to the discovery that GPR68 activation suppresses 
contextual-but not cue-dependent learning and memory, and does so in wild-type but not 
GPR68 knockout mice.44 These data provide the first evidence for a role of GPR68 in 
cognition. Specifically, sustained hippocampal GPR68 activation may contribute to memory 
deficits. Compound 1, which is now commercially available, has been used by the research 
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community, and its PAM activity has been confirmed by other groups.21,45 Compound 1 was 
identified from a ZINC sublibrary of about 3.1 million compounds through a virtual 
screening campaign targeting GPR68.44,46 Thorough SAR studies on the scaffold of 
compound 1 have not been reported to date. Here, we report a comprehensive SAR study at 
the following three regions of compound 1: (1) the aminotriazine core, (2) the benzyl 
alcohol moiety, and (3) the benzylamine moiety (Figure 1). We describe design, synthesis, 
and biological characterization of various analogues. This study has resulted in the 
identification of significantly improved GPR68 PAMs.
RESULTS
Biological Assay and Data Analysis.
We used a GloSensor cAMP assay to characterize all of the synthesized putative GPR68 
PAMs. More specifically, HEK293T cells were transiently transfected with receptor and 
GloSensor cAMP plasmids for proton-mediated receptor activation of Gs−cAMP 
production. To determine allosteric modulator activity, proton concentration responses in the 
absence and presence of increasing concentrations of putative PAMs were quantified and 
results were analyzed using a standard allosteric operational model26–28 in GraphPad Prism. 
Several previously reported compounds44 (1, 20, 30, 55, 61, 62, and 63) were included in 
this study for comparison.
Modifications of the Aminotriazine Core.
To investigate the SAR of the aminotriazine core, we replaced the free amino group on the 
triazine core with a few small alkylamino groups. We also switched the triazine core to a 
pyrimidine core (Scheme 1 and Table 1). These designed compounds were prepared using 
the synthetic routes outlined in Scheme 1. Intermediates 4 and 9 were prepared according to 
the previously reported procedures44 from 2,4,6-trichloro-1,3,5-triazine (2) and 2,6-dichlor-
pyrimidin-4-amine (8). Briefly, alkylamine substitution of one chloro group on 
trichlorotriazine 1 at low temperature provided alkylamino-substituted dichlorotriazines 3. 
Benzylamine substitution of one chloro group on dichlorotriazines 3 or dicholoropyrimidine 
8 at an elevated temperature yielded intermediates 4 or 9, respectively. Suzuki coupling 
between intermediates 4 or 9 and commercially available (2-(hydroxymethyl)phenyl)boronic 
acid provided the designed compounds 5–7 and 10 (Scheme 1).44
As indicated in Table 1, a small monosubstituted amino group on the triazine core is well 
tolerated. Either methylamino (5) or ethylamino (6) group has a minimal effect on allosteric 
parameters or binding affinity. However, dimethylamino group (7) completely eliminates the 
allosteric activity. Replacing the triazine core with a pyrimidine (10) also greatly reduces 
allosteric activity to barely detectable levels. These results suggest that the amino-substituted 
triazine core is critical for the PAM activity. Therefore, the aminotriazine core is maintained 
in the following SAR studies.
Modifications of the Benzyl Alcohol Moiety.
For the benzyl alcohol moiety, we explored a variety of substituents on the phenyl ring 
(Scheme 2 and Table 2). The synthesis of these analogues started with 2-amino-4,6-
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dichloro-1,3,5-triazine (11). Benzylamine substitution of one chloro group on 11 provided 
the common intermediate 12. Suzuki coupling between intermediate 12 and a set of 
commercially available phenylboronic acids provided compounds 13–15, 21, 22–29, 31, and 
32 (Scheme 2A,D). Compound 16 was obtained by reducing acetophenone 15 (Scheme 2B). 
Compounds 18 and 19 were synthesized through reductive aminations of benzaldehyde 17 
with different amines (Scheme 2C). Compounds 37 and 38 were prepared through Suzuki 
coupling between intermediate 12 and synthesized phenylboronic acids 36 bearing ethoxy 
and isopropoxy groups, respectively, followed by formal group reduction (Scheme 2E).
Switching the hydroxymethyl group (1) to hydrogen (13), methyl (14), methyl ketone (15), 
and 1-hydroxylethyl (16) groups is not tolerated and leads to either weak or inactive 
analogues. Replacing the hydroxymethyl group with an aminomethyl group (18) retains 
affinity cooperativity and efficacy cooperativity but with reduced allosteric binding affinity, 
rendering a less effective GPR68 PAM compared to 1. The N-methyl-substituted 
aminomethyl (19) group further reduces allosteric activities and results in a weak PAM. 
Previously, we have demonstrated the importance of the position of the hydroxymethyl 
group: the ortho-hydroxymethyl isomer was much more effective than the meta-
hydroxymethyl isomer to activate GPR68 Gs−cAMP pathway.44 We have confirmed this 
trend by retesting 20 and by comparing the activities of 1 and 20. This trend has also been 
confirmed by comparing the activities of 15 and 21 (two methyl ketone analogues). Based 
on these SAR results, we kept the orthopositioned hydroxymethyl group in subsequent SAR 
studies and explored additional substituents, such as halides and alkoxy groups on the 
phenyl ring. First, we installed fluoro groups at 3- (22), 4- (23), 5- (24), and 6- (25) positions 
on the phenyl ring. Compared to 1, the 3-fluoro analogue 22 is a less effective GPR68 PAM 
due to the decreased efficacy cooperativity and allosteric binding affinity. The 4-fluoro 
analogue 23 shows slightly increased PAM activity compared to compound 1. Interestingly, 
the 6-fluoro analogue 25 has significantly improved affinity cooperativity (log(α) = 1.15 
± 0.14). However, its binding affinity (−log(KB) = 3.69 ± 0.12) is greatly reduced, resulting 
in an overall slightly worse PAM (log(αβ/KB) = 5.19 ± 0.03) than compound 1 (log(αβ/KB) 
= 5.31 ± 0.05). The 5-fluoro analogue 24 is a slightly better PAM (log(αβ/KB) = 5.69 
± 0.04) than 1 due to its slightly improved affinity cooperativity (log(α) = 0.91 ± 0.07) and 
allosteric binding affinity (−log(KB) = 4.58 ± 0.08). Next, we explored compounds with a 
chloro group at 4- (26), 5- (27), and 6- (28) positions on the phenyl ring. Similar to 25, all of 
these chloro analogues show improved affinity cooperativities (log(α) = 1.01 ± 0.08 (26); 
1.20 ± 0.11 (27); and 1.25 ± 0.19 (28)). In addition, these compounds display improved 
allosteric binding affinities (−log(KB) = 4.76 ± 0.14 (26); 4.49 ± 0.19 (27); and 4.43 ± 0.20 
(28)) albeit reduced efficacy cooperativities, resulting in slightly better PAMs (2- to 4-fold) 
than 1. We also explored analogues bearing a methoxy group at different substitution 
positions (29–32). A methoxy group in general leads to reduced allosteric index compared to 
1. Among the four substitution positions, the 4-position (30) is more tolerated while the 6-
position (32) shows least PAM activity. Consequently, we installed ethoxy (37) and 
isopropoxy (38) groups at the 4-position to explore steric effects. The 4-ethoxy group (37) 
slightly improves affinity cooperativity (log(α) = 0.87 ± 0.11), maintains allosteric binding 
affinities, and slightly decreases efficacy cooperativity, resulting in a comparable allosteric 
index to 1. The 4-isopropoxy group (38) shows slightly improved allosteric activity 
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(log(αβ/KB) = 5.74 ± 0.07) compared to 1 due to the increased allosteric binding affinities 
(−log(KB) = 4.91 ± 0.12). These SAR results indicate that additional substituents on the 
benzyl alcohol moiety are tolerated, and appropriate substitutions on the phenyl ring could 
lead to enhanced allosteric activity. Several substituents were identified to improve the 
modulators’ affinity cooperativities and/or allosteric binding affinities. However, none of the 
substituents increased the modulators’ efficacy cooperativities.
Modifications of the Benzylamine Moiety.
To evaluate the effects of the benzylamine moiety on allosteric activity, we designed a 
variety of compounds with differentially substituted benzylamines. In addition, we also 
explored different carbon linker length between the phenyl and amino groups (Table 3). 
These compounds were prepared using nucleophilic aromatic substitution and Suzuki 
coupling reactions described in Scheme 3.
Initially, a series of electron-withdrawing groups (EWGs) such as fluoro (41–43), chloro 
(44–46), and trifluoromethyl (47–49) were introduced to the phenyl moiety to explore their 
effects at different substitution positions. 2-, 3-, and 4-Fluoro groups lead to slightly 
improved allosteric indexes mainly due to the increased affinity cooperativity with log(α) 
values at 0.98 ± 0.15, 0.70 ± 0.13, and 1.09 ± 0.30, respectively. Compared to the fluoro 
substitutions, the chloro substitutions provide more significant allosteric activity 
improvement because of the higher allosteric binding affinities (−log(KB) = 5.07 ± 0.08 
(44), 4.97 ± 0.19 (45), and 5.22 ± 0.07 (46)). Similarly, the trifluoromethyl analogues show 
improved allosteric index due to improved allosteric binding affinities (−log(KB) = 5.05 
± 0.10 (47), 5.11 ± 0.12 (48), and 5.03 ± 0.08 (49)). Thus, EWGs are able to improve the 
modulators’ allosteric activities by increased affinity cooperativities or allosteric binding 
affinities. However, the substitution positions only have moderate effects on the allosteric 
indexes. Next, we explored a couple of electron-donating groups: methyl (50–52) and 
methoxy (52–55). The methyl analogues show slightly improved allosteric indexes mainly 
due to slightly higher allosteric binding affinity (50) or affinity cooperativity (51 and 52). 
Although the 2-, 3-, and 4-methoxy groups improve the affinity cooperativities (log(α) = 
0.98 ± 0.17 (53), 0.89 ± 0.18 (54), and 0.78 ± 0.11 (55)), they reduce the allosteric binding 
affinities, resulting in analogues with reduced allosteric indexes. We subsequently explored a 
few larger alkoxy groups, such as ethoxy (56), isopropoxy (57), cyclopropoxy (58), and 
phenoxy (59), at the 4-position. Interestingly, most of these larger ether substituents 
diminish the efficacy cooperativities, leading to GPR68 α-PAMs, positive allosteric 
modulators with affinity cooperativities (α) greater than 1 and efficacy cooperativities (β) 
equal or close to 1. Compared to 4-methoxy group (55), these larger alkoxy groups enhance 
allosteric binding affinities (−Log(KB) = 4.77 ± 0.03 (56), 4.99 ± 0.09 (57), 5.07 ± 0.12 (58), 
and 5.19 ± 0.14 (59)), leading to improved allosteric activities. In particular, the 4-phenoxy 
analogue (59) is an α-PAM with the most improved allosteric activity compared to 
compound 1. Previously, we have shown that longer carbon linkers between the phenyl and 
amino groups resulted in analogues with higher PAM activity.44 We have now confirmed this 
SAR trend by testing compounds 60–63. While a shorter linker (60) results in reduced 
allosteric index mainly due to the reduced allosteric binding affinity (−log(KB) = 3.92 ± 0.10 
(60)), longer linkers (61–63) enhance allosteric binding affinities (−log(KB) = 4.50 ± 0.21 
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(61), 5.22 ± 0.04 (62), and 5.52 ± 0.12 (63)), leading to improved allosteric indexes. We also 
extended the carbon linker length of the 4-phenoxy-substituted benzylamine analogue 59, 
leading to three analogues 64–66. These analogues, however, do not show enhanced 
allosteric activities compared to 59. Instead, longer linkers lead to reduced allosteric 
activities. Interestingly, these analogues all retain high affinity cooperativity α values. Thus, 
extending the carbon linker length between the phenyl group and amino group does not 
always lead to better PAMs. Importantly, these SAR results suggest that similar to the benzyl 
alcohol moiety, modifications of the benzylamine moiety could improve the modulators’ 
affinity cooperativities and/or allosteric binding affinities, but not their efficacy 
cooperativities.
Combined Modifications of Different Moieties.
The SAR study described above indicates that several functional groups, such as 6-fluoro 
(25)- and 5-chloro (27)-substituted hydroxymethylphenyl moieties and 2-fluoro (41)-, 4-
fluoro (43)-, 3-methyl (51)-, 2-methoxy (53)-, and 4-phenoxy (59)-substituted benzylamine, 
lead to high affinity cooperativities and/or improved allosteric binding affinities. Using these 
preferred moieties, we designed a number of combination compounds, to further improve 
the allosteric activity and obtain potent GPR68 α-PAMs. We also explored different linker 
lengths between the phenyl group and amino group (n = 1–4). Synthesis of these compounds 
is summarized in Scheme 3, and SAR results of these compounds are summarized in Table 
4.
Compared to 25, 2-fluoro (67)-, 4-fluoro (68)-, 3-methyl (69)-, 2-methoxy (70)-, and 4-
phenoxy (71)-substituted benzyl groups retain relatively high affinity cooperativity values 
and show low efficacy cooperativity values. Most strikingly, the 4-phenoxy analogue 71 
displays greatly enhanced allosteric binding affinity (−log(KB) = 5.85 ± 0.12 vs 3.69 ± 0.12 
for compound 25), resulting in a very potent GPR68 α-PAM. Compared to 1, Compound 71 
has 33-fold better allosteric activity (log(αβ/KB) = 6.83 ± 0.08 vs 5.31 ± 0.05 for compound 
1). We have shown that the linker length between the phenyl and amino groups has different 
effects on the allosteric activities, depending on different R5 groups (6–63 and 59, 64 and 65 
(see above)). Extending the carbon linker length of 25 to 2–4 results in compounds 72–74. 
Compared to 25, all of these longer linker analogues maintain high affinity cooperativity 
values and show low efficacy cooperativity values. For allosteric binding affinity, the 2-
carbon linker (72, −Log(KB) = 5.04 ± 0.09) is optimal among the 4 linker lengths explored. 
Extending the carbon linker length of 71 to 2–3 leads to α-PAMs 75 and 76 with retained 
high affinity cooperativities, low efficacy cooperativities, but reduced allosteric binding 
affinities.
To improve the allosteric activity of 27, we also increased the linker length between the 
phenyl group and the amino group. The longer linker analogues 77–79 maintain high affinity 
cooperativities and low efficacy cooperativities and enhance allosteric binding affinities 
(−log(KB) = 5.14 ± 0.11 (77), 5.35 ± 0.06 (78), and 4.98 ± 0.10 (79)) with the 3-carbon 
linker (78) being optimal. Finally, we replaced the benzylamine moiety of 27 with a 4-
phenoxy substituted benzylamine moiety (80) or a 4-phenoxy-substituted homobenzylamine 
moiety (81). Compounds 80 and 81 preserve the α-PAM activity. Compared to 27, both 
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compounds show similar allosteric binding affinities (−log(KB) = 4.70 ± 0.14 (80) and 4.59 
± 0.18 (81)) and similar overall allosteric activities (i.e., log(αβ/KB) values).
Our SAR study has identified several GPR68 PAMs with better allosteric activities than 
compound 1. For example, 46, an αβ-PAM (α and β > 1), has shown 6-fold higher allosteric 
activity (log(αβ/KB) value) than 1. α-PAM 71 has the highest log(αβ/KB) value, which is 
33-fold higher than that of 1. Compounds 77 and 78, α-PAMs, have approximately 10-fold 
better allosteric activity than 1. We selected these four GPR68 PAMs for further 
characterization.
Selectivity Profiles of Selected GPR68 PAMs.
To determine selectivities of 46, 71, 77, and 78 for GPR68 over other closely related proton 
GPCRs, such as GPR4 and GPR65, we tested these GPR68 PAMs against GPR4 and GPR65 
using GloSensor cAMP assays. As shown in Figure 2A–D, GPR4 and GPR65 have different 
response profiles to proton stimulation compared to GPR68 in the absence of modulators. 
The proton potency values (pEC50) were pH 8.04 (Hill slope of 5.25) for GPR4, pH 7.47 
(Hill slope of 4.57) for GPR65, and pH 6.73 (Hill slope of 3.38) for GPR68. In the presence 
of the lead PAM 71 (Figure 2B) as well as 1 (Figure 2A), proton activity at GPR68 is 
potentiated in a PAM concentration-dependent manner (proton concentration-response 
curves were shifted leftward (affinity cooperativity α > 1) and upward (efficacy 
cooperativity β > 1)), while Compound 71 has no PAM activity at GPR4 (Figure 2C) and 
weak potentiation of proton activity at GPR65 only at high concentrations (Figure 2D). 
These data indicate that our lead PAM 71 is selective for GPR68 over the functionally 
related receptors GPR4 and GPR65. Similarly, as illustrated in Supporting Figure 2, 
compounds 46, 77, and 78 show no effect or weak activity only at high concentrations at 
GPR4 and GPR65.
Compounds 46, 71, 77, and 78 were further screened in radioligand binding assays against a 
panel of 48 common drug targets, including GPCRs, neurotransmitter transporters, and 
hERG ion channels. As indicated in Figure 2E and Supporting Figure 3, most of these 
compounds have affinity values higher than 300 nM (pKi = 6.50) at all targets tested. Among 
the tested GPCRs, 5-HT2B has moderate binding affinity (pKi = 6.50–7.00) to 71, 77, and 
78, with Ki values of 219, 209, and 295 nM, respectively. In addition, adenosine 2A (A2A) 
receptor has moderate binding affinity to 46 with Ki value of 300 nM. The compounds with 
binding affinities between 300 and 100 nM (pKi = 6.50–7.00) were further tested in 
functional assays to determine if they acted as agonists or antagonists. At 5-HT2B receptors, 
71, 77, and 78 show no agonist activity but display weak antagonist activity (Supporting 
Figure 4A,B) with functional affinity (Ki) values of 310, 678, and 212 nM, respectively, 
which are comparable to their corresponding binding affinities. At A2A receptors 
(Supporting Figure 4C), 46 displays no agonist activity, but shows weak inverse agonist 
activity with potency of 1700 nM in the absence of reference agonist and antagonist activity 
with functional affinity of 6700 nM.
For lead PAMs with the potential to serve as molecular probes for chemical biology studies, 
it is also desirable to determine their off-target agonist activities at other human GPCRs. 
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Therefore, 46, 71, 77, and 78 were tested against all human GPCRome in our PRESTO-
Tango screening assays.47 As illustrated in Figure 2F, across the whole human GPCRome, 
Compound 71 has agonist activity only at the MT1 and MT2 receptors. Compound 46 shows 
no agonist activity, while compounds 77 and 78 display agonist activity at an atypical 
chemokine receptor 3 (ACKR3) (previously known as CXCR7)48,49 (Supporting Figure 5). 
Subsequent concentration-response assays indicate that 71 is a weak full agonist at the MT1 
receptor (EC50 = 320 nM) and a weak partial agonist activity at the MT2 receptor (EC50 = 
540 nM; Emax = 24%) (Supporting Figure 6). Consistently, 71 displays low binding affinities 
to MT1 (5900 nM) and MT2 (1100 nM) receptors. Compounds 77 and 78 show full agonist 
activities at ACKR3 with EC50 values of 1700 and 690 nM, respectively (Supporting Figure 
6).
Characterization of Selected Lead Modulators at Mouse GPR68.
To assess whether selected human GPR68 PAMs also function as PAMs at mouse GPR68 
receptor, we determined the PAM activity at mouse GPR68 in the absence and presence of 
lead modulators for proton-mediated Gs−cAMP production. As illustrated in Figure 3 and 
Supporting Figure 7, in the absence of modulators, mouse GPR68 responds to proton 
stimulation in a very similar way as human GPR68 with a potency of pH 6.68 (Hill slope of 
2.95). As with human GPR68, the proton activity at mouse GPR68 is also potentiated by the 
lead PAMs 71 (Figure 3), 46, 77, and 78 (Supporting Figure 7) in a concentration-dependent 
manner—shifting proton response curves to the left with increased maxima. Extracted 
allosteric parameters determined by fitting the curves to the operational allosteric model are 
listed in Table 5. Compared to the allosteric activity of these PAMs at human GPCR68, the 
compounds display 2- to 3-fold less allosteric activity at mouse GPR68, suggesting a 
potential small species difference in sensitivity to GPR68 PAMs.
In Vivo Pharmacokinetic (PK) Properties of Compound 71.
After obtaining the promising in vitro potency and selectivity results for Compound 71, we 
assessed in vivo pharmacokinetic properties of this lead compound in mice. Since GPR68 is 
most abundantly expressed in the brain and is associated with learning and memory, it is 
necessary to test whether this compound can penetrate the blood-brain barrier (BBB) in 
animals. A single intraperitoneal injection at the dose of 25 mg/kg led to high exposure 
levels (above 10 μM) in both plasma and brain at 0.5 h in mice (Figure 4). The high 
compound exposure levels in both plasma and brain were maintained for 2 h. These results 
have demonstrated that Compound 71 is bioavailable and can readily cross the BBB in mice. 
Furthermore, there were no clinical signs observed in test mice. Taken together, these results 
suggest that Compound 71 is a valuable chemical tool for investigating biological function 
of GPR68 in vivo.
Characterization of Selected Inactive Analogues.
Compounds 7, 20 (a known inactive analogue of 1),44 and 21 do not show PAM activity at 
GPR68, GPR4, and/or GPR65 (Supporting Figure 8), proton responses are left-shifted by 71 
as expected and are minimally affected by the presence of the inactive analogues, suggesting 
that the inactive analogues do not bind to the allosteric site of GPR68 to antagonize the PAM 
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activity of 71. In addition, inactive analogues 7 and 21 show minimal binding affinities to 
common drug targets (Supporting Figure 3). Moreover, 7 and 21 display no off-target 
agonist activity across the human GPCRome (Supporting Figure 5). Therefore, compounds 
7, 20, and 21 are potentially useful inactive controls for studying GPR68 pharmacology.
DISCUSSION AND CONCLUSIONS
It is worth noting the unique nature of GPR68 pharmacology as the co-binding ligand for the 
allosteric effect, namely, hydrogen ion, is always present. Therefore, GPR68 allosteric 
modulators will likely have direct consequences to cellular signaling: PAMs will produce 
direct agonism, while negative allosteric modulators will produce inverse agonism. In 
addition, differences exist for PAMs depending on whether the allosterism primarily affects 
affinity (α-effect) or efficacy (β-effect). Specifically, α-PAMs (α > 1 and β ≈ 1) will 
produce greater agonism at neutral pH conditions while β-PAMs (α ≈ 1 and β > 1) will 
produce relatively more agonism in acidic environments. The differences in signaling 
produced by α- versus β-modulators are described in detail in the Supporting Information. 
In the present study, we are able to achieve potent and selective GPR68 α-PAMs (e.g., 
compounds 71, 77, and 78) and αβ-PAMs (e.g., compound 46), but not β-PAMs.50–53
There are examples that precipitous changes in allosteric activity may come from apparently 
small changes in molecular structure, known specifically as “activity switching” in the 
PAMs for mGluRs.54–56 In this SAR study, with compound 1 as a scaffold, we also observed 
large changes in allosteric activity (from active PAMs to inactive analogues) with small 
structural modifications to the aminotriazine core and benzyl alcohol group. Further SAR 
and mutational studies are needed to elucidate underlying molecular mechanisms, which 
will aid in designing better modulators.
Depending on the pKa values, the physiochemical properties of modulators, such as net 
charges and H-bonding potential, could change under different pH conditions. 
Correspondingly, binding interactions of modulators with GPR68 could be pH-dependent, 
leading to different levels of receptor activation in both pH- and concentration-dependent 
manner. Therefore, our functional assay is designed to use a wide pH range and is done in 
the absence and presence of increasing concentrations of modulators to generate at least six 
sets of 16-point proton concentration-response curves (each in quadruplicate) in a single 
384-well plate for proper comparison.
To achieve novel brain-penetrant GPR68 PAMs, we tried to maintain low tPSA values by 
utilizing lipophilic substituents on the triazine scaffold. While this strategy successfully led 
to BBB permeable Compound 71, these lipophilic groups could also reduce the aqueous 
solubility of the compounds. Indeed, we have observed bell-shaped proton concentration-
response curves at high compound concentrations (10 and/or 30 μM) for compounds 57–59, 
63–66, 75–78, and 81. The assay signals waned when modulators were tested at pH < 7.40. 
This is likely due to the reduced aqueous solubility of these compounds under acidic 
conditions or aggregation.57,58 Addition of 1 mg/ mL bovine serum albumin (BSA) in assay 
buffers may have improved solubility but did not affect the bell-shaped curves. Under these 
circumstances, we may have slightly under-estimated the allosteric parameters of these 
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compounds, especially with regard to the efficacy cooperativity β. In any case, this effect 
prevented high concentrations of modulators from being included in the functional assays. 
This, in turn, prevented observation of the characteristic saturation (termed the “ceiling 
effect”) of allosteric modulation, further leading to increased levels of variation in estimated 
allosteric parameters.
In summary, we have performed a comprehensive SAR study by exploring three regions of 
the scaffold represented by compound 1. While structural changes on the aminotriazine core 
did not improve the allosteric activity, modifications to the benzyl alcohol and benzylamino 
groups did lead to slightly more active GPR68 PAMs with increased affinity cooperativities 
and allosteric binding affinities. The subsequently designed combination compounds with 
the substituents showing best α and KB values from each region ultimately resulted in much 
improved GPR68 α-PAMs, including Compound 71, which has 33-fold increased allosteric 
activity compared to 1. We also identified a significantly improved αβ-PAM, compound 46. 
We further determined that compounds 71 and 46 and two additional GPR68 PAMs were 
selective for GPR68 over GPR4 and GPR65, two closely related proton GPCRs. In addition, 
these four compounds had no or low off-target agonist activity across the human GPCRome 
and had weak to moderate binding affinity to 48 common GPCRs, ion channels, and 
transporters. Moreover, we demonstrated that our lead compound, 71, is bioavailable in mice 
and has excellent brain penetration. Finally, we identified several potentially useful inactive 
controls. These novel GPR68 PAMs and inactive controls are valuable chemical tools for 
studying GPR68 biology and pharmacology. Furthermore, our study paved the way for 
developing the next generation of GPR68 PAMs and allosteric modulators for other GPCRs.
EXPERIMENTAL SECTION
Chemistry General Procedures.
All chemical reagents were purchased from commercial vendors and used without further 
purification. Dry solvents were purchased from commercial vendors with a verified 
anhydrous standard. Microwave-heated reactions were performed with a Discover SP 
microwave system with an Explorer 12 Hybrid Autosampler by CEM (Buckingham, U.K.). 
EMD Millipore 210–270 μm 60-F254 silica gel plates were used to perform analytical thin-
layer chromatography (TLC). The plates were examined under a UV Lamp. The flash 
column chromatography was conducted using a Teledyne ISCO CombiFlash Rf+ instrument. 
This instrument was also equipped with a variable-wavelength UV detector and a fraction 
collector. RediSep Rf normal phase silica columns were used for purification. Preparative 
high-performance liquid chromatography (HPLC) was used to purify all final compounds. 
HPLC was conducted on an Agilent Prep 1200 series with the UV detector set to 254 nm. 
Samples were injected into a Phenomenex Luna 750 × 30 mm2, 5 μm C18 column. 
Separation was performed at room temperature with a flow rate of 40 mL/min. The linear 
gradient program was set as follows: 10% methanol (A) in H2O containing 0.1% 
trifluoroacetic acid (B) to 100% methanol (A). All compounds for biological evaluation 
were determined to have >95% purity after the purification using the aforementioned prep-
HPLC methods. An Agilent 1200 series system with diode array detector and a 2.1 mm × 
150 mm Zorbax 300SB-C18 5 μm column for chromatography were used to obtain HPLC 
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spectra for all compounds. Samples (0.5 μL) were injected onto a C18 column at room 
temperature. The column flow rate was set to 0.4 mL/min. Chromatography was performed 
with water containing 0.1% formic acid as Solvent A and acetonitrile-containing 0.1% 
formic acid as solvent B. The linear gradient was set as follows: 1% B (0–1 min), 1– 99% B 
(1–4 min), and 99% B (4–8 min). An Agilent G1969A atmospheric pressure interface time 
of flight with an electrospray ionization source was used to acquire high-resolution mass 
spectra data in positive-ion mode. All compounds were also characterized using a Bruker 
(Billerica, MA) DRX-600 nuclear magnetic resonance (NMR) spectrometer (600 MHz, 1H 
NMR). Chemical shifts are reported in parts per million (δ) relative to residual solvent 
peaks. 1H NMR data are reported as follows: chemical shift, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet), coupling constant, and integration.
General Procedures for Preparation of Compounds 5–7.
(2–4-(Benzylamino)-6-(methylamino)-1,3,5-triazin-2-yl)phenyl)-methanol (5).59
—Intermediate 3 was prepared according to previously published procedures starting with 
4,6-dichloro-N-methyl-1,3,5-triazin-2-amine (2) and benzylamine. The white solid 3 (24.9 
mg, 0.1 mmol) was suspended in dioxane (0.8 mL) and water (0.2 mL) in a microwave tube. 
Then, tetrakis(triphenylphosphine)palladium(0) (5.8 mg, 5 mol %), potassium carbonate 
(27.6 mg, 0.2 mmol), and (2-(hydroxymethyl)phenyl)boronic acid (30.4 mg, 0.2 mmol) were 
added. The mixture was heated to 120 °C for 20 min under microwave irradiation. The 
resulting mixture was filtered through Celite with ethyl acetate as eluent solvent. The filter 
was washed with water and extracted with ethyl acetate. The combined organic layers were 
washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The 
resulting residue was dissolved in 1.5 mL of methanol and purified by preparative HPLC to 
yield 7 as a white solid (27 mg, 84%). 1H NMR (600 MHz, CD3OD) δ 7.81 (d, J = 7.8 Hz, 
1H), 7.60 (dd, J = 20.0, 7.4 Hz, 3H), 7.50 (t, J = 7.6 Hz, 1H), 7.43 (d, J = 7.6 Hz, 1H), 7.35 
(t, J = 7.8 Hz, 2H), 7.31–7.24 (m, 1H), 4.81 (s, 2H), 4.72 (d, J = 5.1 Hz, 2H), 3.05 (d, J = 5.3 
Hz, 3H). HRMS m/z [M + H]+ calcd for C18H20N5O+ 322.1662, found 322.1678.
(2-(4-(Benzylamino)-6-(ethylamino)-1,3,5-triazin-2-yl)phenyl)-methanol (6).—
White solid (15.2 mg, 98%). 1H NMR (600 MHz, CD3OD) δ 7.83 (d, J = 7.8 Hz, 1H), 7.69–
7.57 (m, 2H), 7.51 (t, J = 7.6 Hz, 1H), 7.35 (ddt, J = 41.4, 34.0, 7.3 Hz, 5H), 4.81 (s, 2H), 
4.70 (s, 2H), 3.54 (q, J = 7.2 Hz, 2H), 1.22 (t, J = 7.2 Hz, 3H). HRMS m/z [M + H]+ calcd 
for C19H22N5O+ 336.1819, found 336.1873.
(2-(4-(Benzylamino)-6-(dimethylamino)-1,3,5-triazin-2-yl)-phenyl)methanol (7).
—White solid (32 mg, 42%). 1H NMR (600 MHz, CD3OD) δ 7.90 (d, J = 7.8 Hz, 1H), 7.62 
(dd, J = 24.7, 7.5 Hz, 2H), 7.52 (t, J = 7.6 Hz, 1H), 7.42 (d, J = 7.5 Hz, 2H), 7.35 (t, J = 7.4 
Hz, 2H), 7.28 (t, J = 7.3 Hz, 1H), 4.84 (s, 2H), 4.70 (s, 2H), 3.32 (d, J = 24.3 Hz, 6H). 
HRMS m/z [M + H]+ calcd for C19H22N5O+ 336.1819, found 336.1832.
(2-(6-Amino-2-(benzylamino)pyrimidin-4-yl)phenyl)methanol (10).—Compound 
10 was synthesized following the same procedure for preparing 5 starting with 2,6-
dichloropyrimidin-4-amine 8 and benzylamine. The title compound 10 was obtained as a 
white solid (27.2 mg, 92%). 1H NMR (600 MHz, CD3OD) δ 7.57 (d, J = 5.2 Hz, 2H), 7.53–
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7.43 (m, 2H), 7.39 (d, J = 7.6 Hz, 2H), 7.34 (t, J = 7.6 Hz, 2H), 7.27 (t, J = 7.3 Hz, 1H), 6.20 
(s, 1H), 4.66 (s, 2H), 4.62 (s, 2H). HRMS m/z [M + H]+ calcd for C18H19N4O+ 307.1553, 
found 307.1542.
General Procedures for Preparation of Compounds 13–15.
Intermediate 12 was prepared according to previously published procedures.44
N2-Benzyl-6-phenyl-1,3,5-triazine-2,4-diamine (13).—To a dried microwave tube 
were added intermediate 12 (23.6 mg, 0.1 mmol), phenylboronic acid (24.4 mg, 0.2 mmol), 
tetrakis(triphenylphosphine) palladium (5.8 mg, 5 mol %), potassium carbonate (27.6 mg, 
0.2 mmol) dioxane (0.8 mL), and water (0.2 mL). The mixture was heated to 120 °C for 20 
min under microwave irradiation. The resulting mixture was filtered through Celite with 
ethyl acetate as eluent solvent. The filter was washed with water and extracted with ethyl 
acetate. The combined organic layers were washed with brine, dried over anhydrous 
Na2SO4, filtered, and concentrated in vacuo. The resulting residue was dissolved in 1.5 mL 
of methanol and purified by preparative HPLC to yield 13 as a white solid (26 mg, 94%). 1H 
NMR (600 MHz, CD3OD) δ 8.15 (t, J = 6.3 Hz, 2H), 7.69 (q, J = 8.9, 8.2 Hz, 1H), 7.57 (dt, 
J = 11.2, 7.5 Hz, 2H), 7.42–7.30 (m, 4H), 7.27 (q, J = 6.9 Hz, 1H), 4.69 (d, J = 3.8 Hz, 2H). 
HRMS m/z [M + H]+ calcd for C16H N + 16 5 278.1400, found 278.1415.
N2-Benzyl-6-(o-tolyl)-1,3,5-triazine-2,4-diamine (14).—White solid (29 mg, 98%). 1H 
NMR (600 MHz, CD3OD) δ 7.60 (dd, J = 12.1, 7.8 Hz, 1H), 7.51 (t, J = 7.6 Hz, 1H), 7.43–
7.31 (m, 6H), 7.28 (q, J = 7.2, 5.7 Hz, 1H), 4.69 (s, 2H), 2.52 (s, 3H). HRMS m/z [M + H]+ 
calcd for C17H18N5+ 292.1557, found 292.1539.
1-(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)phenyl)ethan-1-one (15).—
White solid (48 mg, 54%). 1H NMR (600 MHz, CD3OD) δ 8.06 (d, J = 7.7 Hz, 1H), 7.89 (t, 
J = 7.9 Hz, 1H), 7.80 (dd, J = 7.7, 3.2 Hz, 1H), 7.73 (dt, J = 11.0, 7.6 Hz, 1H), 7.44–7.23 (m, 
5H), 4.71 (s, 2H), 2.01 (d, J = 2.4 Hz, 3H). HRMS m/z [M + H]+ calcd for C18H18N5O
+ 320.1506, found 320.1531.
1-(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)phenyl)ethan-1-ol (16).—
Compound 15 (15 mg, 0.05 mmol) was dissolved in THF (mL). After the mixture was 
cooled to 0 °C, sodium borohydride (4 mg, 0.1 mmol) was added slowly. The reaction was 
monitored by TLC until 15 disappeared. Methanol (1 mL) was added slowly to quench the 
reaction. The mixture was filtered and concentrated in vacuo. The resulting residue was 
dissolved in 1.5 mL of methanol and purified by preparative HPLC to yield 16 as a white 
solid (16 mg, 51%). 1H NMR (600 MHz, CD3OD) δ 7.76–7.59 (m, 3H), 7.52–7.44 (m, 2H), 
7.43– 7.31 (m, 4H), 7.28 (dd, J = 9.2, 5.7 Hz, 1H), 5.27–5.18 (m, 1H), 4.70 (s, 2H), 1.53 (d, 
J = 6.5 Hz, 3H). HRMS m/z [M + H]+ calcd for C18H20N5O+ 322.1662, found 322.1669.
6-(2-(Aminomethyl)phenyl)-N2-benzyl-1,3,5-triazine-2,4-diamine (18).—
Intermediate 17 (123 mg, 86%) was prepared following the same procedures that were used 
to prepare 13 starting with 2-formylphenyl boronic acid and intermediate 12. To a 
suspension of intermediate 17 (47 mg, 0.15 mmol), magnesium sulfate (200 mg) and 
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NH3·H2O (0.75 mmol, 107 μL) in THF (2 mL) was added sodium borohydride (5.7 mg, 0.15 
mmol) slowly. After stirring for 2 days at room temperature, methanol (1 mL) was added 
slowly to quench the reaction. The mixture was filtered and concentrated in vacuo. The 
resulting residue was dissolved in 1.5 mL of methanol and purified by preparative HPLC to 
yield 18 as yellow oil (21 mg, 45%). 1H NMR (600 MHz, CD3OD) δ 7.83 (d, J = 7.8 Hz, 
1H), 7.64 (t, J = 7.5 Hz, 1H), 7.60 (d, J = 7.5 Hz, 1H), 7.51 (q, J = 7.0, 6.5 Hz, 1H), 7.40 (d, 
J = 7.6 Hz, 1H), 7.37–7.31 (m, 3H), 7.29 (q, J = 7.9, 7.2 Hz, 1H), 4.82 (s, 2H), 4.69 (s, 2H). 
HRMS m/z [M + H]+ calcd for C17H N + 19 6 307.1666, found 307.1676.
N2-Benzyl-6-(2-((methylamino)methyl)phenyl)-1,3,5-triazine-2,4-diamine (19).—
Compound 19 was prepared following the general procedure for preparing compound 18 
from intermediate 17 and methylamine (2 M in THF). Yellow oil (22 mg, 67%). 1H NMR 
(600 MHz, CD3OD) δ 7.69 (dd, J = 7.6, 3.7 Hz, 1H), 7.66–7.49 (m, 3H), 7.39–7.15 (m, 5H), 
4.62 (s, 2H), 4.39 (s, 2H), 2.79 (s, 3H). HRMS m/ z [M + H]+ calcd for C18H N + 21 6 
321.1882, found 321.1877.
General Procedures for Preparation of Compounds 21–29, 31, and 32.
Compounds 21–19, 31 and 32 were prepared following the general procedure for preparing 
compound 13 from intermediate 12 and commercially available substituted phenylboronic 
acids.
1-(3-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)phenyl)ethan-1-one (21).—
White solid (28 mg, 87%). 1H NMR (600 MHz, CD3OD) δ 8.80 (s, 1H), 8.44 (d, J = 7.8 Hz, 
1H), 8.32–8.20 (m, 1H), 7.78–7.63 (m, 1H), 7.47–7.19 (m, 5H), 4.69 (s, 2H), 2.67 (s, 3H). 
HRMS m/z [M + H]+ calcd for C18H18N5O+ 320.1506, found 320.1522.
(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-6-fluorophenyl)-methanol (22).
—White solid (29 mg, 89%). 1H NMR (600 MHz, CD3OD) δ 7.63 (d, J = 7.8 Hz, 1H), 7.53 
(td, J = 8.0, 5.1 Hz, 1H), 7.44–7.32 (m, 5H), 7.28 (t, J = 7.5 Hz, 1H), 4.83 (s, 2H), 4.69 (s, 
2H). HRMS m/z [M + H]+ calcd for C17H17FN5O+ 326.1412, found 326.1435.
(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-5-fluorophenyl)-methanol (23).
—White solid (30 mg, 91%). 1H NMR (600 MHz, CD3OD) δ 7.86 (dt, J = 10.6, 5.3 Hz, 
1H), 7.43–7.30 (m, 5H), 7.30–7.15 (m, 2H), 4.84 (d, J = 5.1 Hz, 2H), 4.67 (d, J = 5.0 Hz, 
2H). HRMS m/z [M + H]+ calcd for C17H17FN5O+ 326.1412, found 326.1426.
(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-4-fluorophenyl)-methanol (24).
—White solid (28 mg, 86%). 1H NMR (600 MHz, CD3OD) δ 7.66–7.57 (m, 2H), 7.42–7.31 
(m, 5H), 7.30–7.24 (m, 1H), 4.78 (s, 2H), 4.69 (s, 2H). HRMS m/z [M + H]+ calcd for 
C17H17FN5O+ 326.1412, found 326.1407.
(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-3-fluorophenyl)-methanol (25).
—White solid (31 mg, 94%). 1H NMR (600 MHz, CD3OD) δ 7.63–7.54 (m, 2H), 7.43–7.31 
(m, 5H), 7.28–7.23 (m, 1H), 4.76 (s, 2H), 4.69 (s, 2H). HRMS m/z [M + H]+ calcd for 
C17H17FN5O+ 326.1412, found 326.1419.
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—White solid (16 mg, 64%). 1H NMR (600 MHz, CD3OD) δ 7.81 (dd, J = 8.4, 2.0 Hz, 1H), 
7.65 (s, 1H), 7.48 (dd, J = 21.4, 8.4 Hz, 1H), 7.41–7.30 (m, 4H), 7.27 (t, J = 7.5 Hz, 1H), 
4.81 (s, 2H), 4.68 (s, 2H). HRMS m/z [M + H]+ calcd for C17H17ClN5O+ 342.1116, found 
342.1111.
(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-4-chlorophenyl)methanol (27).
—White solid (27 mg, 93%). 1H NMR (600 MHz, CD3OD) δ 7.86 (d, J = 2.3 Hz, 1H), 
7.65–7.56 (m, 2H), 7.42–7.32 (m, 4H), 7.28 (t, J = 7.3 Hz, 1H), 4.79 (s, 2H), 4.69 (s, 2H). 
HRMS m/z [M + H]+ calcd for C17H17ClN5O+ 342.1116, found 342.1126.
(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-3-chlorophenyl)methanol (28).
—White solid (6.8 mg, 78%). 1H NMR (600 MHz, CD3OD) δ 7.42–7.30 (m, 3H), 7.26–
7.09 (m, 5H), 4.53 (s, 2H), 4.49 (s, 2H). HRMS m/z [M + H]+ calcd for C17H17ClN5O
+ 342.1116, found 342.1123.
(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-6-methoxyphenyl)methanol 
(29).—White solid (13 mg, 84%). 1H NMR (600 MHz, CD3OD) δ 7.48 (t, J = 8.1 Hz, 1H), 
7.40 (d, J = 7.2 Hz, 1H), 7.37–7.31 (m, 4H), 7.29 (dd, J = 7.8, 3.5 Hz, 2H), 4.82 (s, 2H), 
4.69 (s, 2H), 3.91 (s, 3H). HRMS m/z [M + H]+ calcd for C18H20N5O2+ 338.1612, found 
338.1618.
(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-4-methoxyphenyl)methanol 
(31).—White solid (28 mg, 86%). 1H NMR (600 MHz, CD3OD) δ 7.47 (dd, J = 8.6, 5.9 Hz, 
1H), 7.44 (d, J = 2.8 Hz, 1H), 7.40 (d, J = 7.2 Hz, 1H), 7.35 (t, J = 7.6 Hz, 3H), 7.31–7.24 
(m, 1H), 7.17 (dd, J = 8.5, 2.7 Hz, 1H), 4.72 (d, J = 2.8 Hz, 2H), 4.69 (d, J = 2.9 Hz, 2H), 
3.86 (s, 3H). HRMS m/z [M + H]+ calcd for C18H20N5O2+ 338.1612, found 338.1614.
(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-3-methoxyphenyl)methanol 
(32).—White solid (16 mg, 48%). 1H NMR (600 MHz, CD3OD) δ 7.54 (td, J = 8.2, 3.0 Hz, 
1H), 7.42–7.32 (m, 4H), 7.29 (tt, J = 8.5, 4.8 Hz, 1H), 7.13 (dd, J = 7.9, 5.6 Hz, 2H), 4.68 (s, 
2H), 4.68 (s, 2H), 3.88 (d, J = 1.6 Hz, 3H). HRMS m/z [M + H]+ calcd for 
C18H20N5O2+ 338.1612, found 338.1625.
General Procedures for Preparation of Compounds 37 and 38.—Intermediate 36 
was prepared according to previously published procedures.60
(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-5-ethoxyphenyl)methanol (37).
—To a dried microwave tube were added intermediate 12 (23.6 mg, 0.1 mmol), intermediate 
36 (39.2 mg, 0.2 mmol), tetrakis(triphenylphosphine)palladium(0) (5.8 mg, 5 mol %), 
potassium carbonate (27.6 mg, 0.2 mmol %), dioxane (0.8 mL), and water (0.2 mL). The 
mixture was heated to 120 °C for 20 min under microwave. The resulting mixture was 
filtered through Celite with ethyl acetate as eluent solvent. The filter was washed with water 
and extracted with ethyl acetate. The combined organic layers were washed brine, dried over 
anhydrous Na2SO4, filtered, and concentrated in vacuo. The resulting residue was dissolved 
in 5 mL of THF. After the mixture was cooled to 0 °C, sodium borohydride (11 mg, 0.3 
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mmol) was added slowly. The reaction was warmed to room temperature and stirred for 10 
min before methanol was added slowly to quench the reaction. The mixture was washed 
with water and extracted with ethyl acetate. Combined organic layers were washed with 
water, brine, dried over Na2SO4, filtered, and concentrated in vacuo. The resulting residue 
was dissolved in 1.5 mL of methanol and purified by preparative HPLC to yield 37 as a 
white solid (3.7 mg, 23%). 1H NMR (600 MHz, CD3OD) δ 7.68 (d, J = 7.9 Hz, 2H), 7.60 (d, 
J = 8.1 Hz, 2H), 7.35–7.30 (m, 3H), 6.29 (s, 1H), 4.10 (s, 2H), 3.65 (s, 2H), 2.65–2.51 (q, J 
= 7.2 Hz, 2H), 1.49 (t, J = 7.2 Hz, 3H). HRMS m/z [M + H]+ calcd for 
C19H22N5O2+ 352.1768, found 352.1762.
(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-5-isopropoxyphenyl)methanol 
(38).—White solid (32 mg, 88%). 1H NMR (600 MHz, CD3OD) δ 7.86 (d, J = 8.7 Hz, 1H), 
7.39 (d, J = 7.3 Hz, 1H), 7.37–7.30 (m, 3H), 7.27 (t, J = 7.3 Hz, 1H), 7.14 (d, J = 2.6 Hz, 
1H), 7.00 (dd, J = 8.8, 2.7 Hz, 1H), 4.81 (s, 2H), 4.78–4.72 (m, 1H), 4.68 (s, 2H), 1.35 (d, J 
= 6.0 Hz, 6H). HRMS m/z [M + H]+ calcd for C20H24N5O2+ 366.1925, found 366.1934.
General Procedures for Preparation of Compounds 41–54, 56–60, and 64–81.
Intermediate 40 was prepared from intermediates 3 and 11 and commercially available 
amines (intermediate 39) according to the previously reported procedures.44 Compounds 
41–54, 56–60, and 64–66 were prepared following the general procedure for preparing 
compound 13 from intermediate 40 and (2-(hydroxymethyl)phenyl)boronic acid. 
Compounds 67–81 were prepared following the general procedure for preparing compound 
13 from intermediate 40 and substituted (2-(hydroxymethyl)phenyl)-boronic acids.
(2-(4-Amino-6-((2-fluorobenzyl)amino)-1,3,5-triazin-2-yl)-phenyl)methanol (41).
—White solid (27 mg, 82%). 1H NMR (600 MHz, CD3OD) δ 7.82 (d, J = 7.7 Hz, 1H), 
7.65–7.54 (m, 2H), 7.47 (dt, J = 26.2, 7.6 Hz, 2H), 7.33–7.25 (m, 1H), 7.13 (t, J = 7.7 Hz, 
1H), 7.07 (t, J = 9.3 Hz, 1H), 4.79 (d, J = 3.9 Hz, 2H), 4.74 (s, 2H). HRMS m/z [M + H]+ 
calcd for C17H17FN5O+ 326.1412, found 326.1443.
(2-(4-Amino-6-((3-fluorobenzyl)amino)-1,3,5-triazin-2-yl)-phenyl)methanol (42).
—White solid (27 mg, 83%). 1H NMR (600 MHz, CD3OD) δ 7.82 (d, J = 7.8 Hz, 1H), 
7.65–7.56 (m, 2H), 7.49 (t, J = 7.9 Hz, 1H), 7.32 (td, J = 8.0, 5.7 Hz, 1H), 7.21–7.10 (m, 
2H), 6.98 (td, J = 8.5, 2.6 Hz, 1H), 4.81 (s, 2H), 4.68 (s, 2H). HRMS m/z [M + H]+ calcd for 
C17H17FN5O+ 326.1412, found 326.1435.
(2-(4-Amino-6-((4-fluorobenzyl)amino)-1,3,5-triazin-2-yl)-phenyl)methanol (43).
—White solid (26 mg, 80%). 1H NMR (600 MHz, CD3OD) δ 7.81 (dt, J = 7.9, 4.7 Hz, 1H), 
7.72–7.53 (m, 3H), 7.49 (dd, J = 7.9, 4.8 Hz, 1H), 7.39 (dt, J = 9.7, 5.0 Hz, 1H), 7.03 (tt, J = 
8.7, 4.5 Hz, 2H), 4.80 (t, J = 4.9 Hz, 2H), 4.64 (d, J = 4.9 Hz, 2H). HRMS m/z [M + H]+ 
calcd for C17H17FN5O+ 326.1412, found 326.1438.
(2-(4-Amino-6-((2-chlorobenzyl)amino)-1,3,5-triazin-2-yl)-phenyl)methanol (44).
—White solid (32 mg, 94%). 1H NMR (600 MHz, CD3OD) δ 7.84 (d, J = 7.7 Hz, 1H), 
7.68–7.58 (m, 2H), 7.54–7.47 (m, 2H), 7.41 (dd, J = 7.2, 2.0 Hz, 1H), 7.29 (ddt, J = 9.4, 6.9, 
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4.0 Hz, 2H), 4.83 (s, 2H), 4.79 (s, 2H). HRMS m/z [M + H]+ calcd for C17H17ClN5O
+ 342.1116, found 342.1113.
(2-(4-Amino-6-((3-chlorobenzyl)amino)-1,3,5-triazin-2-yl)-phenyl)methanol (45).
—White solid (26 mg, 78%). 1H NMR (600 MHz, CD3OD) δ 7.83 (d, J = 7.4 Hz, 1H), 
7.70–7.57 (m, 2H), 7.51 (td, J = 7.5, 1.5 Hz, 1H), 7.43 (d, J = 2.1 Hz, 1H), 7.36–7.19 (m, 
3H), 4.83 (s, 2H), 4.69 (s, 2H). HRMS m/z [M + H]+ calcd for C17H17ClN5O+ 342.1116, 
found 342.1102.
(2-(4-Amino-6-((4-chlorobenzyl)amino)-1,3,5-triazin-2-yl)-phenyl)methanol (46).
—White solid (18 mg, 52%). 1H NMR (600 MHz, CD3OD) δ 7.83 (dd, J = 7.9, 1.2 Hz, 1H), 
7.67–7.58 (m, 2H), 7.51 (td, J = 7.5, 1.5 Hz, 1H), 7.38 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 9.0 
Hz, 2H), 4.82 (s, 2H), 4.67 (s, 2H). HRMS m/z [M + H]+ calcd for C17H17ClN5O
+ 342.1116, found 342.1108.
(2-(4-Amino-6-((2-(trifluoromethyl)benzyl)amino)-1,3,5-triazin-2-
yl)phenyl)methanol (47).—White solid (35 mg, 93%). 1H NMR (600 MHz, CD3OD) δ 
7.86 (d, J = 7.7 Hz, 1H), 7.72 (t, J = 6.7 Hz, 1H), 7.67–7.55 (m, 4H), 7.53 (td, J = 7.5, 1.5 
Hz, 1H), 7.47 (td, J = 7.4, 2.2 Hz, 1H), 4.93 (s, 2H), 4.85 (s, 2H). HRMS m/z [M + H]+ 
calcd for C18H17F3N5O+ 376.1380, found 376.1388.
(2-(4-Amino-6-((3-(trifluoromethyl)benzyl)amino)-1,3,5-triazin-2-
yl)phenyl)methanol (48).—White solid (35 mg, 94%). 1H NMR (600 MHz, CD3OD) δ 
7.83 (d, J = 7.6 Hz, 1H), 7.73–7.46 (m, 7H), 4.83 (s, 2H), 4.78 (s, 2H). HRMS m/z [M + H]+ 
calcd for C18H17F3N5O+ 376.1380, found 376.1367.
(2-(4-Amino-6-((4-(trifluoromethyl)benzyl)amino)-1,3,5-triazin-2-
yl)phenyl)methanol (49).—White solid (36 mg, 96%). 1H NMR (600 MHz, CD3OD) δ 
7.83 (dd, J = 7.8, 1.3 Hz, 1H), 7.67–7.55 (m, 3H), −6.76 (m, 1H), 4.82 (s, 2H), 4.66 (s, 2H), 
3.78 (s, 3H). HRMS m/z [M + H]+ calcd for C18H17F3N5O+ 376.1380, found 376.1374.
(2-(4-Amino-6-((2-methylbenzyl)amino)-1,3,5-triazin-2-yl)-phenyl)methanol (50).
—White solid (28 mg, 88%). 1H NMR (600 MHz, CD3OD) δ 7.82 (d, J = 7.7 Hz, 1H), 
7.64–7.54 (m, 2H), 7.54–7.44 (m, 1H), 7.35–7.22 (m, 1H), 7.19–7.12 (m, 3H), 4.80 (s, 2H), 
4.68 (s, 2H), 2.35 (s, 3H). HRMS m/z [M + H]+ calcd for C18H20N5O+ 322.1662, found 
322.1654.
(2-(4-Amino-6-((3-methylbenzyl)amino)-1,3,5-triazin-2-yl)-phenyl)methanol (51).
—White solid (29 mg, 92%). 1H NMR (600 MHz, CD3OD) δ 7.81 (d, J = 7.7 Hz, 1H), 
7.68–7.55 (m, 2H), 7.50 (td, J = 7.5, 1.6 Hz, 1H), 7.25–7.13 (m, 3H), 7.08 (d, J = 7.3 Hz, 
1H), 4.81 (s, 2H), 4.65 (s, 2H), 2.31 (s, 3H). HRMS m/z [M + H]+ calcd for C18H20N5O
+ 322.1662, found 322.1657.
(2-(4-Amino-6-((4-methylbenzyl)amino)-1,3,5-triazin-2-yl)-phenyl)methanol (52).
—White solid (22 mg, 69%). 1H NMR (600 MHz, CD3OD) δ 7.81 (d, J = 7.7 Hz, 1H), 
7.70–7.57 (m, 2H), 7.55–7.47 (m, 1H), 7.27 (d, J = 7.8 Hz, 2H), 7.15 (d, J = 7.7 Hz, 2H), 
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4.81 (s, 2H), 4.64 (s, 2H), 2.29 (s, 3H). HRMS m/z [M + H]+ calcd for C18H20N5O
+ 322.1662, found 322.1672.
(2-(4-Amino-6-((2-methoxybenzyl)amino)-1,3,5-triazin-2-yl)-phenyl)methanol 
(53).—White solid (27 mg, 79%). 1H NMR (600 MHz, CD3OD) δ 7.80 (d, J = 7.8 Hz, 1H), 
7.66–7.58 (m, 2H), 7.49 (t, J = 7.6 Hz, 1H), 7.38–7.18 (m, 2H), 7.04–6.74 (m, 2H), 4.80 (s, 
2H), 4.67 (s, 2H), 3.85 (s, 3H). HRMS m/z [M + H]+ calcd for C18H20N5O2 + 338.1612, 
found 338.1623.
(2-(4-Amino-6-((3-methoxybenzyl)amino)-1,3,5-triazin-2-yl)-phenyl)methanol 
(54).—White solid (29 mg, 87%). 1H NMR (600 MHz, CD3OD) δ 7.83 (dd, J = 7.8, 1.3 Hz, 
1H), 7.67–7.55 (m, 3H), −6.76 (m, 1H), 4.82 (s, 2H), 4.66 (s, 2H), 3.78 (s, 3H). HRMS m/z 
[M + H]+ calcd for C18H20N5O2+ 338.1612, found 338.1618.
(2-(4-Amino-6-((4-ethoxybenzyl)amino)-1,3,5-triazin-2-yl)-phenyl)methanol (56).
—White solid (32 mg, 93%). 1H NMR (600 MHz, CD3OD) δ 7.81 (t, J = 6.4 Hz, 1H), 7.69–
7.55 (m, 2H), 7.55–7.46 (m, 1H), 7.31 (td, J = 7.8, 7.0, 3.6 Hz, 1H), 6.95–6.79 (m, 3H), 4.81 
(s, 2H), 4.60 (s, 2H), 4.00 (q, J = 6.7 Hz, 2H), 1.36 (t, J = 6.7 Hz, 3H). HRMS m/z [M + H]+ 
calcd for C19H22N5O2+ 352.1768, found 352.1765.
(2-(4-Amino-6-((4-isopropoxybenzyl)amino)-1,3,5-triazin-2-yl)-phenyl)methanol 
(57).—White solid (3.2 mg, 52%). 1H NMR (600 MHz, CD3OD) δ 7.83 (dd, J = 7.8, 1.3 
Hz, 1H), 7.70–7.55 (m, 2H), 7.51 (td, J = 7.6, 1.5 Hz, 1H), 7.36–7.16 (m, 1H), 6.98–6.73 (m, 
3H), 4.81 (s, 2H), 4.61 (s, 2H), 4.60–4.53 (m, 1H), 1.29 (d, J = 6.0 Hz, 6H). HRMS m/z [M 
+ H]+ calcd for C20H24N5O2+ 366.1925, found 366.1928.
(2-(4-Amino-6-((4-cyclopropoxybenzyl)amino)-1,3,5-triazin-2-
yl)phenyl)methanol (58).—White solid (30 mg, 84%). 1H NMR (600 MHz, CD3OD) δ 
7.83 (d, J = 7.8 Hz, 1H), 7.62 (dt, J = 21.8, 7.4 Hz, 2H), 7.51 (t, J = 7.5 Hz, 1H), 7.33 (d, J = 
8.2 Hz, 2H), 7.02 (d, J = 8.2 Hz, 2H), 4.81 (s, 2H), 4.62 (s, 2H), 3.80–3.71 (m, 1H), 0.77 (t, J 
= 6.3 Hz, 2H), 0.66 (t, J = 2.9 Hz, 2H). HRMS m/z [M + H]+ calcd for 
C20H22N5O2+ 364.1768, found 364.1776.
(2-(4-Amino-6-((4-phenoxybenzyl)amino)-1,3,5-triazin-2-yl)-phenyl)methanol 
(59).—White solid (13.4 mg, 84%). 1H NMR (600 MHz, CD3OD) δ 7.82 (dd, J = 7.8, 1.2 
Hz, 1H), 7.65–7.56 (m, 3H), 7.56–7.46 (m, 2H), 7.40 (d, J = 8.6 Hz, 1H), 7.32 (dd, J = 8.6, 
7.3 Hz, 2H), 7.09 (t, J = 7.4 Hz, 1H), 6.95 (d, J = 8.5 Hz, 3H), 4.81 (s, 2H), 4.65 (s, 2H). 
HRMS m/z [M + H]+ calcd for C23H22N5O2+ 400.1768, found 400.1743.
(2-(4-Amino-6-(phenylamino)-1,3,5-triazin-2-yl)phenyl)-methanol (60).—White 
solid (28 mg, 96%). 1H NMR (600 MHz, CD3OD) δ 7.88 (d, J = 7.6 Hz, 1H), 7.75 (d, J = 
7.9 Hz, 2H), 7.64 (dt, J = 17.2, 7.7 Hz, 2H), 7.53 (t, J = 7.5 Hz, 1H), 7.39 (t, J = 7.9 Hz, 2H), 
7.21 (t, J = 7.4 Hz, 1H), 4.87 (s, 2H). HRMS m/z [M + H]+ calcd for C16H16N5O
+ 294.1349, found 294.1341.
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phenyl)methanol (64).—White solid (32 mg, 77%). 1H NMR (600 MHz, CD3OD) δ 7.82 
(dd, J = 7.7, 1.3 Hz, 1H), 7.67–7.57 (m, 3H), 7.51 (td, J = 7.6, 1.4 Hz, 1H), 7.35–7.19 (m, 
4H), 7.08 (t, J = 7.3 Hz, 1H), 6.93 (dd, J = 8.6, 6.8 Hz, 3H), 4.79 (s, 2H), 3.73 (t, J = 7.3 Hz, 
2H), 2.94 (t, J = 7.4 Hz, 2H). HRMS m/z [M + H]+ calcd for C24H24N5O2+ 414.1925, found 
414.1945.
(2-(4-Amino-6-((3-(4-phenoxyphenyl)propyl)amino)-1,3,5-triazin-2-
yl)phenyl)methanol (65).—White solid (18 mg, 87%). 1H NMR (600 MHz, CD3OD) δ 
7.83 (d, J = 7.8 Hz, 1H), 7.70–7.56 (m, 3H), 7.51 (t, J = 7.3 Hz, 1H), 7.31 (t, J = 7.7 Hz, 
1H), 7.21 (d, J = 8.2 Hz, 2H), 7.07 (t, J = 7.4 Hz, 1H), 6.97–6.78 (m, 4H), 4.81 (s, 2H), 3.52 
(t, J = 7.0 Hz, 2H), 2.71 (t, J = 6.1 Hz, 2H), 2.08–1.86 (m, 2H). HRMS m/z [M + H]+ calcd 
for C25H26N5O2+ 428.2081, found 428.2076.
(2-(4-Amino-6-((4-(4-phenoxyphenyl)butyl)amino)-1,3,5-triazin-2-
yl)phenyl)methanol (66).—White solid (17 mg, 73%). 1H NMR (600 MHz, CD3OD) δ 
7.82 (d, J = 7.8 Hz, 1H), 7.63 (dt, J = 22.8, 7.7 Hz, 3H), 7.52 (t, J = 7.5 Hz, 1H), 7.30 (q, J = 
6.2, 4.7 Hz, 1H), 7.19 (d, J = 8.2 Hz, 2H), 7.06 (t, J = 7.4 Hz, 1H), 6.91 (dd, J = 23.1, 8.2 
Hz, 4H), 4.81 (s, 2H), 3.52 (t, J = 6.4 Hz, 2H), 2.66 (q, J = 6.4 Hz, 2H), 1.70 (dt, J = 7.9, 3.9 
Hz, 4H). HRMS m/z [M + H]+ calcd for C26H28N5O2+ 442.2238, found 442.2234.
(2-(4-Amino-6-((2-fluorobenzyl)amino)-1,3,5-triazin-2-yl)-3-
fluorophenyl)methanol (67).—White solid (33 mg, 96%). 1H NMR (600 MHz, CD3OD) 
δ 7.54 (td, J = 8.0, 5.5 Hz, 1H), 7.45 (td, J = 7.6, 1.7 Hz, 1H), 7.38 (d, J = 7.8 Hz, 1H), 7.34–
7.26 (m, 1H), 7.23–7.13 (m, 2H), 7.13–7.04 (m, 1H), 4.71 (s, 2H), 4.68 (s, 2H). HRMS m/z 
[M + H]+ calcd for C17H16F2N5O+ 344.1317, found 344.1321.
(2-(4-Amino-6-((4-fluorobenzyl)amino)-1,3,5-triazin-2-yl)-3-
fluorophenyl)methanol (68).—White solid (32 mg, 92%). 1H NMR (600 MHz, CD3OD) 
δ 7.58 (td, J = 8.0, 5.5 Hz, 1H), 7.44–7.31 (m, 3H), 7.25–7.19 (m, 1H), 7.08 (t, J = 8.6 Hz, 
2H), 4.72 (s, 2H), 4.65 (s, 2H). HRMS m/z [M + H]+ calcd for C17H16F2N5O+ 344.1317, 
found 344.1323.
(2-(4-Amino-6-((3-methylbenzyl)amino)-1,3,5-triazin-2-yl)-3-
fluorophenyl)methanol (69).—White solid (32 mg, 94%). 1H NMR (600 MHz, CD3OD) 
δ 7.61–7.53 (m, 1H), 7.39 (d, J = 7.7 Hz, 1H), 7.26–7.15 (m, 4H), 7.14–7.05 (m, 1H), 4.73 
(s, 2H), 4.64 (s, 2H), 2.34 (s, 3H). HRMS m/z [M + H]+ calcd for C18H19FN5O+ 340.1568, 
found 340.1562.
(2-(4-Amino-6-((2-methoxybenzyl)amino)-1,3,5-triazin-2-yl)-3-
fluorophenyl)methanol (70).—White solid (32 mg, 91%). 1H NMR (600 MHz, CD3OD) 
δ 7.62–7.54 (m, 1H), 7.42–7.37 (m, 1H), 7.33 (dd, J = 7.4, 2.2 Hz, 1H), 7.31–7.26 (m, 1H), 
7.26–7.20 (m, 1H), 6.98 (dd, J = 8.4, 2.1 Hz, 1H), 6.96–6.88 (m, 1H), 4.73 (s, 2H), 4.66 (s, 
2H), 3.86 (s, 3H). HRMS m/z [M + H]+ calcd for C18H19FN5O2+ 356.1517, found 
356.1523.
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fluorophenyl)methanol (71).—White solid (16 mg, 75%). 1H NMR (500 MHz, CD3OD) 
δ 7.59 (td, J = 8.1, 5.6 Hz, 1H), 7.43–7.37 (m, 3H), 7.36–7.30 (m, 2H), 7.27–7.21 (m, 1H), 
7.13–7.07 (m, 1H), 6.99–6.95 (m, 4H), 4.73 (s, 2H), 4.65 (s, 2H); 13C NMR (126 MHz, 
CD3OD) δ 163.70, 163.17, 162.58, 160.59, 158.72, 158.44, 144.72, 134.40, 133.79, 131.03, 
130.77, 125.63, 124.64, 120.03, 120.01, 116.34, 116.17, 62.66, 45.33. HRMS m/z [M + H]+ 
calcd for C23H21FN5O2+ 418.1674, found 418.1665.
(2-(4-Amino-6-(phenethylamino)-1,3,5-triazin-2-yl)-3-fluorophenyl)methanol 
(72).—White solid (30 mg, 89%). 1H NMR (600 MHz, CD3OD) δ 7.60 (td, J = 8.2, 5.5 Hz, 
1H), 7.41 (t, J = 8.8 Hz, 1H), 7.35–7.14 (m, 6H), 4.73 (d, J = 2.9 Hz, 2H), 3.71 (t, 2H), 2.95 
(t, J = 7.5 Hz, 2H). HRMS m/z [M + H]+ calcd for C18H19FN5O+ 340.1568, found 
340.1577.
(2-(4-Amino-6-((3-phenylpropyl)amino)-1,3,5-triazin-2-yl)-3-
fluorophenyl)methanol (73).—White solid (25 mg, 71%). 1H NMR (600 MHz, CD3OD) 
δ 7.60 (td, J = 8.1, 5.6 Hz, 1H), 7.40 (d, J = 7.8 Hz, 1H), 7.29–7.23 (m, 2H), 7.23–7.10 (m, 
4H), 4.73 (s, 2H), 3.50 (t, J = 7.2 Hz, 2H), 2.71 (t, J = 7.2 Hz, 2H), 2.04–1.89 (m, 2H). 
HRMS m/z [M + H]+ calcd for C19H21FN5O+ 354.1725, found 354.1735.
(2-(4-Amino-6-((4-phenylbutyl)amino)-1,3,5-triazin-2-yl)-3-
fluorophenyl)methanol (74).—White solid (23 mg, 64%). 1H NMR (600 MHz, CD3OD) 
δ 7.65–7.56 (m, 1H), 7.40 (t, J = 6.6 Hz, 1H), 7.24 (ddt, J = 8.9, 5.1, 2.6 Hz, 3H), 7.21–7.17 
(m, 2H), 7.14 (tt, J = 7.2, 1.5 Hz, 1H), 4.74 (s, 2H), 3.50 (t, 2H), 2.67 (t, J = 7.0 Hz, 2H), 
1.81–1.53 (m, 4H). HRMS m/z [M + H]+ calcd for C20H23FN5O+ 368.1881, found 
368.1883.
(2-(4-Amino-6-((4-phenoxyphenethyl)amino)-1,3,5-triazin-2-yl)-3-
fluorophenyl)methanol (75).—White solid (19 mg, 88%). 1H NMR (600 MHz, CD3OD) 
δ 7.75–7.49 (m, 4H), 7.41 (t, J = 8.4 Hz, 1H), 7.32 (ddd, J = 8.6, 6.0, 2.1 Hz, 1H), 7.29–7.18 
(m, 2H), 7.07 (t, J = 7.4 Hz, 1H), 6.99–6.85 (m, 3H), 4.73 (s, 2H), 3.72 (t, J = 7.4 Hz, 2H), 
2.94 (t, J = 7.3 Hz, 2H). HRMS m/z [M + H]+ calcd for C24H23FN5O2+ 432.1830, found 
432.1832.
(2-(4-Amino-6-((3-(4-phenoxyphenyl)propyl)amino)-1,3,5-triazin-2-yl)-3-
fluorophenyl)methanol (76).—White solid (16 mg, 70%). 1H NMR (600 MHz, CD3OD) 
δ 7.64–7.46 (m, 1H), 7.39 (d, J = 7.4 Hz, 1H), 7.31 (ddd, J = 8.7, 7.4, 1.5 Hz, 2H), 7.26–
7.13 (m, 4H), 7.07 (t, J = 7.4 Hz, 1H), 7.01–6.77 (m, 3H), 4.68 (s, 2H), 3.48 (t, J = 7.1 Hz, 
2H), 2.70 (t, J = 7.7 Hz, 2H), 2.06–1.83 (m, 2H). HRMS m/z [M + H]+ calcd for 
C25H25FN5O2+ 446.1987, found 446.1978.
(2-(4-Amino-6-(phenethylamino)-1,3,5-triazin-2-yl)-4-chlorophenyl)methanol 
(77).—White solid (15 mg, 43%). 1H NMR (600 MHz, CD3OD) δ 7.84 (d, J = 2.2 Hz, 1H), 
7.70–7.52 (m, 3H), 7.36–7.08 (m, 4H), 4.77 (s, 2H), 3.72 (t, J = 7.5 Hz, 2H), 2.95 (t, J = 7.6 
Hz, 2H). HRMS m/z [M + H]+ calcd for C18H19ClN5O+ 356.1273, found 356.1278.
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chlorophenyl)methanol (78).—White solid (7 mg, 19%). 1H NMR (600 MHz, CD3OD) 
δ 7.86 (t, J = 1.7 Hz, 1H), 7.68–7.54 (m, 3H), 7.35–7.05 (m, 4H), 4.77 (s, 2H), 3.50 (t, J = 
7.0 Hz, 2H), 2.71 (t, J = 7.7 Hz, 2H), 2.06–1.86 (m, 2H). HRMS m/z [M + H]+ calcd for 
C19H21ClN5O+ 370.1429, found 370.1423.
(2-(4-Amino-6-((4-phenylbutyl)amino)-1,3,5-triazin-2-yl)-4-
chlorophenyl)methanol (79).—White solid (12 mg, 32%). 1H NMR (600 MHz, 
CD3OD) δ 7.86 (t, J = 3.4 Hz, 1H), 7.69–7.52 (m, 3H), 7.33–7.00 (m, 4H), 4.76 (s, 2H), 
3.58–3.44 (m, 2H), 2.67 (q, J = 7.5, 6.9 Hz, 2H), 1.70 (tdd, J = 9.8, 5.3, 2.7 Hz, 4H). HRMS 
m/z [M + H]+ calcd for C20H23ClN5O+ 384.1586, found 384.1589.
(2-(4-Amino-6-((4-phenoxybenzyl)amino)-1,3,5-triazin-2-yl)-4-
chlorophenyl)methanol (80).—White solid (8 mg, 18%). 1H NMR (600 MHz, CD3OD) 
δ 7.91–7.87 (m, 1H), 7.63–7.53 (m, 2H), 7.39 (d, J = 8.5 Hz, 2H), 7.35–7.30 (m, 2H), 7.10 
(t, J = 7.6 Hz, 1H), 6.99–6.93 (m, 4H), 4.75 (s, 2H), 4.64 (s, 2H). HRMS m/z [M + H]+ 
calcd for C23H21ClN5O2+ 434.1387, found 434.1376.
(2-(4-Amino-6-((4-phenoxyphenethyl)amino)-1,3,5-triazin-2-yl)-4-
chlorophenyl)methanol (81).—White solid (16 mg, 36%). 1H NMR (600 MHz, 
CD3OD) δ 7.86 (d, J = 2.2 Hz, 1H), 7.57 (dt, J = 10.6, 8.4 Hz, 2H), 7.38–7.19 (m, 4H), 
7.13–7.04 (m, 1H), 7.01–6.81 (m, 4H), 4.74 (s, 2H), 3.78–3.65 (m, 2H), 2.93 (t, J = 7.5 Hz, 
2H). HRMS m/z [M + H]+ calcd for C24H23ClN5O2+ 448.1535, found 448.1537.
Calcium Release Assays.
Calcium release assays for Gq-GPCRs were performed according to published protocol61 
with minor modifications. In brief, HEK293 cells stably expressing 5-HT2B receptors62 were 
plated in 384-well black clear bottom plates (coated with poly-L-Lys) at a density of 10 000 
cells/well in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 1% 
dialyzed fetal bovine serum (dFBS) overnight (16–20 h). The cells were loaded with Fluo-4 
Direct Calcium dye (20 μL/well) for 1 h at 37 °C in FLIPR buffer [1× Hank’s balanced salt 
solution (HBSS), 20 mM 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES), 
and 2.5 mM probenecid, pH 7.40, room temperature]. Drug working dilutions (3× of final) 
were prepared in the FLIPR buffer supplemented with 1 mg/ mL BSA and 0.1 mg/mL 
ascorbic acid. The FLIPRTETRA was programmed to transfer 10 μL/well of drug solution, 
and fluorescence was recorded for a total of 2 min with 1 read/s and 10 s before drug 
addition. The maximum fluorescence intensity (fold of basal) within the first minute of drug 
addition was exported and analyzed in Prism.
GloSensor cAMP Assays.
Proton-mediated GPR68 Gs activation was determined by measuring cAMP production 
using GloSensor cAMP assays as reported previously44 with modifications as detailed 
below. Calcium- and magnesium-free Hank’s balanced salt solution (1× HBSS) was used as 
the base for all pH buffers. Different zwitterionic organic buffer agents were used for 
different pH ranges, 1× HBSS with 20 mM 2-(N-morpholino)ethanesulfonic acid for pH 
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5.60–6.70, 1× HBSS with 20 mM 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid 
(HEPES) for pH 6.80–8.20, and 1× HBSS with 20 mM 
(tris(hydroxymethyl)methylamino)propanesulfonic acid (TAPS) for pH 8.30–8.60. The pH 
was adjusted with KOH and fresh buffers were made in the morning to use within 24 h. The 
phosphodiesterase (PDE) inhibitor Ro 20–1724 (10 μM) was included in assay buffer to 
eliminate potential effect of PDE inhibition. BSA (1 mg/mL) was added to buffer for 
samples with solubility issues. Addition of BSA does not affect GloSensor cAMP assays and 
is routinely applied in cell-based GPCR functional assays.63,64 Briefly, HEK293T cells were 
co-transfected with a modified polyethylenimine (PEI) transfection method.65 For a 10 cm 
dish of HEK293T cells with 12 mL growth medium, 4 μg of receptor DNA and 4 μg of 
GloSensor DNA were mixed in 0.4 mL of Opti-MEM medium, followed by addition of 40 
μL PEI reagent (increase proportionally when larger dishes are used). The mixture was 
incubated for 20 min at room temperature and then added to cells for incubation overnight 
(16–20 h). Transfected cells were plated in poly-L-Lys-coated 384-well white clear bottom 
plates using DMEM + 1% dFBS for a minimum of 6 h (up to 24 h) before being used for 
assays. After culture medium was removed, the cells were incubated with 20 μL/well of 3.5 
mM luciferin prepared in assay buffer (1× HBSS, 20 mM TAPS, pH 8.40) for 1 h at 37 °C. 
Ligand stock was made in dimethyl sulfoxide at 10 mM and diluted with pH buffers to 
desired concentrations. To stimulate cells with premixed drug solutions at desired pH 
conditions, luciferin-loading solution was removed before addition of drug solution (25 μL/
well). Luminescence was counted at 20–30 min after drug application, and data were 
analyzed in the GraphPad Prism.
GPCRome Off-Target Agonist Assays.
Off-target agonist activity was carried out according to previously published procedure using 
the PRESTO-Tango assay platform47 with modifications as outlined below. The assay was 
designed and modified such that 40 receptors were tested in each 384-well plate, each in 
quadruplicate wells for basal (with medium vehicle) and in quadruplicate for sample. Each 
plate also contained 16 wells of dopamine D2 receptors stimulated with 100 nM quinpirole 
as assay controls and 16 wells of D2 with vehicle alone as D2 basal activity. In addition, 
there were two columns of wells (32 wells) of untransfected cells as negative controls. The 
whole procedure takes 3 days from plating cells to reading plates. In brief, HTLA cells were 
plated in poly-L-Lys-coated 384-well white clear bottom plates in DMEM supplemented 
with 2% dFBS (10 000 cells per 40 μL per well) overnight, transfected with receptor Tango 
constructs (15 ng/well) overnight using an in-plate PEI transfection method,65 in which 
receptor DNA was resuspended in Opti-MEM and hybridized with PEI reagent prior to 
dilution and distribution to 384-well plates and subsequent addition to cells. After overnight 
incubation, cells received drugs without replacement of the medium and were incubated 
overnight. Drug solutions and medium were removed and Bright-Glo reagent (20 μL/well) 
were added. Luminescence was counted on a luminescence reader after 20 min incubation at 
room temperature. Results were presented in the form of fold of basal for each receptor and 
analyzed in the Prism.
For Tango arrestin recruitment concentration responses with individual GPCRs, HTLA cells 
were transfected with receptor DNA overnight in DMEM with 10% FBS and plated into 
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poly-L-Lys-coated 384-well plates as above using DMEM supplemented with 1% dFBS. 
Drugs were added 6 h later and incubated overnight (16–20 h). Medium and drug solutions 
were removed, and Bright-Glo reagent (20 μL/well) was added. Luminescence was counted 
and results were analyzed in Prism.
Radioligand Binding Assays.
Ligand binding profiling was performed by the NIMH PDSP. The NIMH PDSP is directed 
by Bryan L Roth, MD, PhD, at the University of North Carolina at Chapel Hill, North 
Carolina, and Program Officer Jamie Driscoll at NIMH, Bethesda, MD. Details about 
binding assay procedures and protocols are available online at: https://pdspdb.unc.edu/
pdspWeb/?site= assays.
Data Analysis.
Proton-mediated GPR68 Gs activity, as measured as relative luminescence unit, in the 
absence and presence of increasing concentrations of ligands was fitted to the standard 
allosteric operational model to obtain allosteric parameters, affinity cooperativity α and 
efficacy cooperativity β, and allosteric ligand binding affinity KB.26–28 Briefly, affinity 
cooperativity α defines the reciprocal effect between allosteric modulator and orthosteric 
agonist (protons in this case) with α > 1 for increasing affinity and 0 < α < 1 for reducing 
affinity. Efficacy cooperativity β defines the effect of allosteric modulator on the efficacy of 
the orthosteric agonist (protons in this case) with β > 1 for increasing proton efficacy and 0 
< β < 1 for reducing proton efficacy. The KB defines the equilibrium binding affinity of test 
allosteric ligands in the absence of orthosteric agonist (H+). Since orthosteric agonist protons 
always exist in the receptor compartment, KB in this case has no physical meaning. We 
applied the comprehensive index log(αβ/KB) to quantify the overall allosteric activity of test 
allosteric ligand and the difference from that of reference ligand, ΔLog(αβ/KB), to represent 
the net change of allosteric activity.31 For summary, results were normalized to the 
percentages, pooled together, and analyzed in the Prism. Normalization was performed using 
the built-in normalization function in the Prism, where proton basal activity in the absence 
of test allosteric ligand was set as 0% and the maximum proton activity in the absence of test 
allosteric ligand was set as 100%. In functional antagonist assays, functional affinity (Ki) 
values were calculated from IC50 values using the Cheng-Prusoff equation Ki = IC50/(1 + L/ 
EC50),66 where IC50 is the antagonist concentration when 50% inhibition is achieved against 
reference agonist at concentration [L], EC50 is the potency of the reference agonist.
Mouse Pharmacokinetic Study.—A standard PK study was performed. Compound 71 
was dissolved in 5% N-methyl-2-pyrrolidone, 5% Solutol HS-15, and 90% normal saline. 
Nine male Swiss Albino mice were treated with Compound 71 intraperitoneally at the 25 
mg/kg dose. Plasma and brain samples were collected at 0.5, 1.0, and 2.0 h. Compound 
concentrations in plasma and brain at each time point are average values from three test 
mice. The error bars represent ± SEM.
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ABBREVIATIONS
GPCR G protein-coupled receptor
SAR structure-activity relationship
GS stimulatory G protein
cAMP cyclic adenosine monophosphate
PAM positive allosteric modulator
MT1 melatonin receptor 1
MT2 melatonin receptor 2
ACKR3 atypical chemokine receptor 3
5-HT2B 5-hydroxytryptamine receptor 2B
mGLuR5 metabotropic glutamate receptor 5
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Chemical structure of 1 and three highlighted regions for SAR study.
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Selectivity of the GPR68 PAM 71. Proton concentration-response curves in the absence and 
presence of increasing concentrations of 1 at human GPR68 (A), 71 at human GPR68 (B), 
GPR4 (C), and GPR65 (D). Proton-mediated Gs−cAMP production was measured in 
HEK293T cells transiently transfected with GPR68, GPR4, or GPR65, and GloSensor 
cAMP plasmids. Results were normalized to the proton activity in the absence of modulator 
and represented means ± SEM from a minimum of three independent assays, each in 
quadruplicate. Curves were analyzed in Prism using the built-in four parameter logistic 
functions. (E) Selectivity of 71 over 48 common GPCRs, ion channels, and transporters in 
radioligand binding assays. Values represent average binding affinity (pKi) from a minimum 
of three independent assays, each in triplicate. Targets with less than 50% inhibition at 10 
μM (in quadruplicate) are not shown. BZP for benzodiazepine receptor; DAT for dopamine 
transporter; DOR for delta (δ) opioid receptor; hERG for human ether-a-go-go-related 
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potassium channel; KOR for kappa (κ) opioid receptor; MOR for mu (μ) opioid receptor; 
NET for noradrenaline transporter; PBR for peripheral benzodiazepine binding site; SERT 
for serotonin transporter. (F) Off-target agonist activity of 71 at human GPCRome. 71 was 
screened across the human GPCRome (318 GPCRs) for off-target agonist activity at 1 μM 
using the PRESTO-Tango screening platform. Results (fold of basal) represent means of 
four replicates. Dopamine receptor D2 with 100 nM quinpirole served as an assay control. 
The dashed lines indicate an arbitrary cutoff line at 3× fold of basal.
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Allosteric potentiation of proton activity by Compound 71 at mouse GPR68. Gs GloSensor 
cAMP assays were carried out in HEK293T cells transiently transfected with mouse GPR68 
as with human GPR68. Proton concentration responses were measured in the absence and 
presence of increasing concentrations of modulator. Results were normalized to proton 
activity in the absence of modulator and represented means ± SEM from a minimum of three 
independent assays, each in quadruplicate. Curves were analyzed in Prism. Allosteric 
parameters are summarized in Table 5.
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Mouse pharmacokinetic profile of Compound 71. Compound concentrations were quantified 
in both plasma (red curve) and brain (blue curve) at 0.5, 1.0, and 2.0 h after a single 25 
mg/kg intraperitoneal (IP) administration. Compound concentrations in plasma and brain at 
each time point are average values from three test mice. The error bars represent ± SEM.
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Scheme 1. Synthesis of 5–7 and 10a
aReagents and conditions: (a) tetrahydrofuran (THF), 0 °C to room temperature (rt), 48–
67%; (b) dioxane, reflux, 1 h, 56–96%; (c) Pd(PPh3)4, K2CO3, dioxane/H2O = 5:3, 120 °C, 
microwave, 20 min, 42–98%.
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Scheme 2. Synthesis of 13–15, 21, 16, 18, 19, 22–29, 31, 32, 37, and 38a
aReagents and conditions: (a) dioxane, reflux, 1 h, 78–94%; (b) Pd(PPh3)4, K2CO3, 
dioxane/H2O = 5:3, 120 °C, microwave, 20 min, 56–99%; (c) NaBH4, MeOH, 0 °C to rt, 
42%; (d) NH3·H2O or NH2Me, MgSO4, NaBH4, THF, rt, 2 days, 45–67%. (e) Ethylene 
glycol, toluene, reflux, 4–8 h, 82–96%; (f) alkyl bromide, K2CO3, dimethylformamide, 
85 °C, 34–78%; (g) i. n-BuLi, THF, −78 °C, 30 min; ii. B(OMe)3, −78 °C, 1 h, then rt, 
overnight; iii. HCl (3 N), rt, 1 h, 26–57%; (h) 12, Pd(PPh3)4, K2CO3, dioxane/H2O = 5:3, 
120 °C, microwave, 20 min; (i) NaBH4, THF, 0 °C to rt, 23–97%.
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Scheme 3. Synthesis of 41–54, 56–60, and 64–81a
aReagents and conditions: (a) dioxane, reflux, 1 h, 75–96 %; (b) Pd(PPh3)4, K2CO3, 
dioxane/H2O = 5:3, 120 °C, microwave, 20 min, 16–99%.
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